Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Suppository for treating mammal endometritis

An endometritis, mammalian technology, applied in the directions of suppository delivery, drug combination, medical preparations with inactive ingredients, etc., can solve the problems of small distribution area of ​​drugs in the uterus, unfavorable infiltration into the uterine mucosa, and effects on uterine recovery. , to achieve non-toxic side effects, overcome the effects of irritating, strong bactericidal effect

Active Publication Date: 2012-07-11
昆山博青生物科技有限公司
View PDF7 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] The technical problem to be solved by the present invention is to provide a biocidal effervescent suppository for mammalian endometritis, to overcome the inconvenience of use in the prior art, and the recovery of the uterus is affected by repeated excessive washing of the uterus during treatment , the drug distribution area in the uterus is small, the retention time is short, and the interaction with the mucous membrane liquefaction is weak, which is not conducive to the disadvantages of penetrating into the uterine mucous membrane

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Suppository for treating mammal endometritis
  • Suppository for treating mammal endometritis
  • Suppository for treating mammal endometritis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Embodiment 1 Composite enzyme suppository preparation method 1 (prescription 1)

[0029] 1. Composition and ratio

[0030] Lysostaphin 0.007%, lysozyme 0.1%, F6820%, HPMC 10%, sodium bicarbonate 10%, sodium dihydrogen phosphate 30%, semi-synthetic fatty acid glyceride 29.893%.

[0031] 2. Preparation

[0032]Weigh 0.007 g of lysostaphin, 0.1 g of lysozyme, 20 g of F68, 10 g of HPMC, 10 g% of sodium bicarbonate, and 30 g of sodium dihydrogen phosphate. The above raw materials are crushed through a 80-mesh sieve, mixed evenly, evenly mixed with 29.893 g of molten semi-synthetic fatty acid glycerides, and quickly poured into suppository molds to form.

Embodiment 2

[0033] Embodiment 2 Composite enzyme suppository preparation method 2 (prescription 2)

[0034] 1. Composition and ratio

[0035] Lysostaphin 0.004%, lysozyme 2%, F6810%, HPMC 20%, sodium bicarbonate 20%, sodium dihydrogen phosphate 10%, semi-synthetic fatty acid glyceride 37.996%.

[0036] 2. Preparation

[0037] Weigh 0.004 g of lysostaphin, 2 g of lysozyme, 10 g of F68, 20 g of HPMC, 20 g% of sodium bicarbonate, and 10 g of sodium dihydrogen phosphate. The above raw materials are crushed through an 80-mesh sieve, mixed evenly, evenly mixed with 37.996 g of molten semi-synthetic fatty acid glycerides, and quickly poured into a suppository mold to form.

Embodiment 3

[0038] Embodiment 3 Composite enzyme suppository preparation method 3 (prescription 3)

[0039] 1. Composition and ratio

[0040] Lysostaphin 0.01%, lysozyme 4%, F681%, HPMC 1%, sodium bicarbonate 30%, sodium dihydrogen phosphate 20%, semi-synthetic fatty acid glyceride 43.99%.

[0041] 2. Preparation

[0042] Weigh 0.01 g of lysostaphin, 4 g of lysozyme, F681 g, 1 g of HPMC, 30 g% of sodium bicarbonate, and 20 g of sodium dihydrogen phosphate. The above raw materials are crushed through an 80-mesh sieve, mixed evenly, evenly mixed with 43.99 g of molten semi-synthetic fatty acid glyceride, and quickly poured into a suppository mold to form.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of medicines, and specifically relates to a suppository for treating mammal endometritis. The preparation disclosed in the invention comprises the following components of: by weight, 0.004-0.01% of staphylococcus lysozyme, 0.1-4% of lysozyme, 10-80% of semisynthetic fatty glyceride, 1-20% of poloxamer 188(F68), 1-20% of HPMC, 5-50% of sodium bicarbonate and 5-50% of sodium dihydrogen phosphate. After the preparation provided by the invention enters into mammal uterus through administration, the preparation can undergo effervescence decomposition in a body fluid. The medicine is mixed in foams and rapidly released. Contact area between the medicine and mucosal of uterus becomes larger and the medicine can penetrate into deep portions of mucosa wrinkles so as to prolong the action time between the medicine and the mucosa, raise the concentration of the medicine on local tissues, further enhance the curative effect and effectively kill various pathogens which can cause endometritis.

Description

technical field [0001] The invention relates to a pharmaceutical preparation, in particular to a suppository for treating mammalian endometritis. Background technique [0002] Endometritis is a common disease in mammals such as cows and pigs. The etiology is complex and the incidence rate is high. The incidence of endometritis in dairy cows is between 15% and 20%, while the incidence of the disease in pig farms is about 30%. Endometritis can prolong the time of uterine involution and disturb the estrus cycle. Inflammatory exudate can change the pH of the uterine environment, which is not conducive to the survival of sperm and eggs, reduces the conception rate, and leads to infertility. At the same time, it can also stimulate the receptors on the inner wall of the uterus for a long time, and through reflexes, it can cause hormone imbalance and cause ovarian diseases. . In addition, secondary mastitis can also occur. [0003] At present, antibiotics are used in the treatm...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/48A61K47/38A61K9/02A61P15/00A61K38/47
Inventor 黄青山汪益涵李国栋陆锦春
Owner 昆山博青生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com